Viral infections:

Indications for: EMTRIVA

HIV-1 infection, in combination with other antiretroviral agents.

Adult Dosage:

≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.

Children Dosage:

<3mos: use oral soln. 3mos–17yrs (≤33kg): use oral soln; (>33kg): 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see full labeling).

Boxed Warning:

Posttreatment exacerbation of hepatitis B.

EMTRIVA Warnings/Precautions:

Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.

EMTRIVA Classification:

Nucleoside analogue (reverse transcriptase inhibitor).

EMTRIVA Interactions:

Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).

Adverse Reactions:

Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.


Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.

How Supplied:

Caps—30; Soln—170mL